• FDA approves IND for PSC’s stem cell therapy candidate for Covid-19 pharmaceutical-business-review
    August 06, 2020
    Calidi Biotherapeutics said that the Investigational New Drug (IND) application submitted by its partner, Personalized Stem Cells, Inc. (PSC), has received FDA approval for the treatment of COVID-19 and pneumonia patients using stem cell therapy.
PharmaSources Customer Service